<DOC>
	<DOCNO>NCT01328171</DOCNO>
	<brief_summary>The aim trial optimize response rate rate secondary resection metastases patient initially non-resectable metastatic colorectal cancer RAS wildtype . The patient treat two therapy group : Experimental arm A : Chemotherapy FOLFOXIRI + panitumumab Standard arm B : Chemotherapy FOLFOXIRI</brief_summary>
	<brief_title>FOLFOXIRI With Without Panitumumab Metastatic Colorectal Cancer ( VOLFI )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Cohort I : Histologically confirm definitively inoperable irresectable metastatic colorectal cancer . Focus patient large tumor load metastatic site and/or symptomatic metastatic disease Cohort II : Chance secondary resection curative intent define review expert panel Adult patient ( ≥ 18 year age ) RAS wildtype test KRAS exon 2 ( codon 12/13 ) KRAS exon 3 ( codon 59/61 ) KRAS exon 4 ( codon 117/146 ) NRAS exon 2 ( codon 12/13 ) NRAS exon 3 ( codon 59/61 ) NRAS exon 4 ( codon 117/146 ) assess institution participate certify specific work group Deutsche Gesellschaft für Pathologie ) At least one measurable lesion accord RECIST measure within 3 week prior registration No previous chemotherapy metastatic disease ( adjuvant chemotherapy nonmetastatic disease allow terminate 6 month ago ) Performance status ECOG 01 Male female subject &gt; 18 year age Adequate haematological , hepatic , renal metabolic function parameter : Leukocytes &gt; 3000/mm³ , ANC ≥ 1500/mm3 , platelet ≥ 100,000/mm3 , Hb &gt; 9g/dl ( may transfuse treat erythropoietin maintain exceed level ) Creatinine clearance ≥ 50 ml/min serum creatinine ≤ 1.5 x upper limit normal Bilirubin ≤ 1.5 x upper limit normal , GOTGPT ≤ 2.5 x upper limit normal absence liver metastasis , ≤ 5 x upper limit normal presence liver metastasis , AP ≤ 5 x upper limit normal Magnesium ≥ low limit normal ; calcium ≥ low limit normal ( may substitute maintain exceed level ) Negative pregnancy test willingness use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment ( adequate : oral contraceptive , intrauterine device barrier method conjunction spermicidal jelly ) . Before subject registration , write informed consent must give accord ICHGCP , national/local regulation . Past current history malignancy except indication study curatively treat : Basal squamous cell carcinoma skin Insitu carcinoma cervix Other malignant disease without recurrence least 5 year followup Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 6 month enrolment . Clinically relevant interstitial lung disease , e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . History evidence upon physical examination CNS disease unless adequately treat ( e.g . primary brain tumour , seizure control standard medical therapy , brain metastasis history stroke ) . Preexisting neuropathy &gt; grade 1 ( NCI CTCAE ) , except loss tendon reflex Allogeneic transplantation require immunosuppressive therapy . Severe nonhealing wound , ulcer bone fraction . Evidence bleed diathesis coagulopathy . Patients receive therapeutic anticoagulation must INR &lt; 1,5 ULN aPTT &lt; 1,5 ULN within 7 day prior randomization . The use full dose anticoagulant allow long INR aPTT within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant least two week time randomisation . Concomitant therapy certain antiviral medicine ( sorivudine brivudine analogue compound ) . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start , anticipation need major surgical procedure course study except surgery colorectal cancer curative intent central venous line placement chemotherapy administration . Pregnancy breastfeed woman . Subjects know allergy study drug excipients . Known DPD deficiency . Current recent ( within 28 day prior start study treatment ) treatment another investigational drug participation another investigational study . Known grade III/IV allergic reaction monoclonal antibody . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss subject registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>